Table 4

 Changes in levels of rheumatoid factor and anti-cyclic citrullinated peptide antibodies assessed before and after 1 year of treatment according to the anti-tumour necrosis factor agent used

TreatmentLevel*
Baseline1 yearp Value
Anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid arthritis.
*Median value (interquartile range).
Anti-CCPInfliximab30.48 (14.08–73.21)30.25 (6.43–64.86)0.071
Etanercept26.82 (3.7–87.72)28.98 (3.46–104.87)0.084
Adalimumab35.64 (2.23–75.02)36.78 (2.23–67.6)0.426
All31.18 (6.22–78.95)30.89 (4.56–66.25)0.589
RF (nephelometry)Infliximab115 (43.3–290.3)65 (25.65–166.25)<0.001
Etanercept61 (17.67–367)54 (17.25–200)0.036
Adalimumab64 (15–259.75)30 (11.5–130.75)0.003
All90 (22.5–304.5)51.7 (17–163)<0.001
IgM-RFInfliximab41.3 (17.07–117.05)30.9 (15.82–67.42)<0.001
Etanercept23.55 (7.25–86.25)22.35 (5.2–70.95)0.034
Adalimumab17.6 (6.67–84.97)11.7 (5.07–31.77)0.048
All29.9 (10.8–104.5)23.45 (9.15–64)<0.001
IgA-RFInfliximab64.2 (22.1–179.4)41.8 (17.42–92.42)<0.001
Etanercept23.7 (6.45–109)22.7 (8.3–33.47)0.004
Adalimumab16.9 (8.8–33.47)12.3 (7.37–30.35)0.067
All30.1 (10.85–144.35)28.6 (9.45–83.5)<0.001
IgG-RFInfliximab61.6 (28.87–156.8)42.6 (24.72–75.95)<0.001
Etanercept58.35 (33.35–181.1)53.5 (28.45–127.6)0.144
Adalimumab27.5 (12.5–76.1)20.5 (12.8–28.62)0.096
All48 (24.2–132.9)38.8 (19.7–86.3)<0.001